Committed to developing novel medicines to transform the lives of patients with life-altering central nervous system (CNS) disorders


SAGE Therapeutics (NASDAQ: SAGE) is a clinical-stage biopharmaceutical company committed to developing novel medicines to transform the lives of patients with life-altering central nervous system (CNS) disorders. SAGE has a portfolio of novel product candidates targeting critical CNS receptor systems, GABA and NMDA. SAGE's lead program, SAGE-547, is in Phase 3 clinical development for super-refractory status epilepticus, a rare and severe seizure disorder. SAGE is developing its next generation modulators, including SAGE-217 and SAGE-689, with a focus on acute and chronic CNS disorders.


Year Invested: 2011
Location: Cambridge, Mass.
Visit: www.sagerx.com

Recent News

December 7, 2017
Sage Therapeutics to Present at BMO Prescriptions for Success Healthcare Conference

December 7, 2017
Sage Therapeutics Reports Positive Top-line Results from Phase 2 Placebo-Controlled Trial of SAGE-217 in Major Depressive Disorder

December 4, 2017
Sage Therapeutics Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

Read More News

Associated Team Members

Kevin Starr
Partner